October 23, 2018

Randox Laboratories Ltd.   
Randox Laboratori   
Pauline Armstrong Senior QA/Regula   
55 Diamond Road   
Cru

Re: K182042 K182042 Trade/Device Name: Randox Calcium Regulation Number: 21 CFR 862.1145 Regulation Name: Calcium Regulatory Class: C Product Code: CJY Dated: July 27, 2018

Dear Pauline Armstrong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, th enactment date of the Medical Device Amendments, or to devices that have been reclassified in accorda with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of controls provisions of the Act. Although this letter refers to your product as a device, please be aware that controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Data located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual re listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to cont

If yur devic is classifid (ee above into either class II (Specil Controls)or class III (MA), it my be If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Co Federal Regulations, Title 21, Parts 800 to 898.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA Please be advised that FDA's issuance of a substantial equivalence determination does not mean that F has made a determination that your device complies with other requirements of the Act or any Feder

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Pa 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CF 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products ( https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, i applic

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR P 807.97). For questions regarding the reporting of adverse events under the MDR regulation

For comprehensive regulatory information about medical devices and radiation-emitting products, including   
For comprehensive regulatory information about medical devices   
information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry an   
Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website   
(http://www.fda.gov/DICE) for mor

![](images/93b4c269e50e0183d6838a22fad58ad57b6ea8a1b66accf88a1342a7c715d643.jpg)

for Courtney H. Lias, Ph.D. Courtney Director Division of Chemistry and To ffice of In Vitro Diagnos and Radiological Health

Enclosure

<table><tr><td>DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use</td><td>Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.</td></tr><tr><td>510(k) Number (if known)</td><td></td></tr><tr><td>K182042</td><td></td></tr><tr><td>Device Name</td><td></td></tr><tr><td>RANDOX CALCIUM (Ca)</td><td></td></tr></table>

The Randox Calcium (Ca) deviceLVintended for the quantitative in vitro determination of calcium concentration in serum, plasma and urine. This product is suitable for use on the RX series analyzer, RX daytona plus. Such measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases and chronic renal failure.

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# RANDOX 510(k) Summary: RANDOX CALCIUM (Ca)

# 1. SAFETY AND EFFECTIVENESS AS REQUIRED BY 21 CFR 807.92 STATEMENT

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirement 21 CFR 807.92.

# 2. SUBMITTER NAME AND ADDRESS

Name: Dr Pauline Armstrong

Address: Randox Laboratories Limited 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom.

Telephone: $+ 4 4$ (0) 28 9442 2413 Fax: $+ 4 4$ (0) 28 9445 2912 E-mail: Pauline.Armstrong@randox.com

Date of Summary Preparation: 16 October 2018

# 3. 510k NUMBER, DEVICE PROPRIETARY NAME, COMMON NAME, PURPOSE FOR SUBMISSION, REGULATORY CLASSIFCATION, PANEL, PRODUCT CODE AND 21 CFR NUMBER

510k No: k182042

Device Proprietary Name: RANDOX CALCIUM (Ca)

Common Name: RANDOX CALCIUM (Ca)

Purpose for Submission: New Device

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Regulation Name</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CJY</td><td rowspan=1 colspan=1>Calcium testsystem</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR 862.1145</td><td rowspan=1 colspan=1>Clinical Chemistry75</td></tr></table>

# Confidential

# 4. PREDICATE DEVICE PROPRIETARY NAMES AND 510 (k) NUMBERS

Predicate Device Proprietary Name: ADVIA Chemistry Calcium_2 (CA_2) Method, 510(k) Number: K083386

# 5. INTENDED USE

The Randox Calcium (Ca) device is intended for the quantitative in vitro determination of calcium concentration in serum, plasma and urine. This product is suitable for use on the RX series analyzer RX daytona plus. Such measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases and chronic renal failure.

# 6. DEVICE DESCRIPTION

The Randox Calcium (Ca) kit consists of a ready to use reagent solution.

CATALOGUE NUMBER: CA8309

R1. Arsenazo III Reagent

4 x 20 ml

# REAGENT COMPOSITION

# Confidential

# 7. PREDICATE DEVICE COMPARISON TABLE

Comparison of the Randox Calcium (Ca), with the Advia Chemistry Calcium_2 (CA_2) Method

<table><tr><td rowspan=1 colspan=1>CHARACTERISTICS</td><td rowspan=1 colspan=1>ADVIAChemistry  Calcium_2(CA_2)Method510(k) k083386</td><td rowspan=1 colspan=1>Randox Calcium (Ca)510(k) k182042</td></tr><tr><td rowspan=1 colspan=1>INTENDED USE</td><td rowspan=1 colspan=1>A calcium test system intended for thequantitative in vitro determination of calciumconcentration in serum, plasma and urine onthe ADVIA Chemistry systems,</td><td rowspan=1 colspan=1>A calcium test system intended for thequantitative in vitro determination ofcalcium concentration in serum, plasmaand urine on the RX series analyser RXdaytona plus.</td></tr><tr><td rowspan=1 colspan=1>ASSAY PROTOCOL</td><td rowspan=1 colspan=1>Arsenazo III</td><td rowspan=1 colspan=1>Arsenazo III</td></tr><tr><td rowspan=1 colspan=1>STORAGE(UNOPENED)</td><td rowspan=1 colspan=1>Reagents stable to expiry when stored at+15 to +25 ° C</td><td rowspan=1 colspan=1>Reagents stable to expiry when stored at+15 to +25 °C</td></tr><tr><td rowspan=1 colspan=1>SAMPLE TYPE</td><td rowspan=1 colspan=1>Human serum, plasma &amp; urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>REAGENTCOMPOSITION</td><td rowspan=1 colspan=1>Sodium acetate (pH 5.9)    54.4 mmol/lArsenazo III                   188μmol/lNon-reactive stabilizers</td><td rowspan=1 colspan=1>Sodium acetate (pH 5.9)       54.4 mmol/lArsenazo               approx. 230μmol/INon-reactive stabilizers</td></tr><tr><td rowspan=1 colspan=1>FORMAT</td><td rowspan=1 colspan=1>Liquid ready to use</td><td rowspan=1 colspan=1>Liquid ready to use</td></tr><tr><td rowspan=1 colspan=1>MEASURINGRANGE</td><td rowspan=1 colspan=1>Serum/Plasma 1.0 mg/dL - 16 mg/dLUrine             1.0 mg/dL - 32 mg/dL</td><td rowspan=1 colspan=1>Serum/Plasma    1.0 mg/dL - 16 mg/dLUrine               1.0 mg/dL - 32 mg/dL</td></tr><tr><td rowspan=1 colspan=1>DEVICECLASSIFICATION</td><td rowspan=1 colspan=1>Calcium test system</td><td rowspan=1 colspan=1>Calcium test system</td></tr></table>

The Randox Calcium (Ca) device has the same intended use as the predicate device. Any differences in the technical characteristics between the candidate and predicate device do not affect the safety or effectiveness. Therefore, the Randox Calcium (Ca) device demonstrates substantial equivalence to the predicate device.

# 8. TEST PRINCIPLE

Arsenazo III specifically binds to Calcium ions to form a coloured complex at 660nm.

$\mathsf { C a ^ { 2 + } + }$ Arsenazo III

Ca-Arsenazo III Complex (purple)

The amount of calcium present in the sample is directly proportional to the intensity of the coloured complex formed.

# Confidential

# RANDOX 510(k) Summary: RANDOX CALCIUM (Ca)

# 9. PERFORMANCE CHARACTERISTICS

Analytical performance:

a. Precision/Reproducibility:

Precision was evaluated consistent with C.L.S.I documents EP05-A3 ‘Evaluation of Precision of Quantitative Measurement Procedures: Approved Guideline – Third Edition.

Precision studies were performed on one RX daytona plus system using two levels of controls, calibration material and human serum samples for Calcium.

Urine precision studies were performed for Calcium using two levels of urine controls, calibration material and human urine samples for Calcium.

Testing was conducted twice per day for 20 non consecutive days. Two replicates per run were performed for each sample.

The results are summarized in the tables below:

# Calcium Serum Precision Summary

Lot 1   

<table><tr><td rowspan=1 colspan=3>System: RX daytona plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum Level 1</td><td rowspan=1 colspan=1>3.89</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum Level 2</td><td rowspan=1 colspan=1>6.61</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>SerumLevel 3</td><td rowspan=1 colspan=1>10.78</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum Level 4</td><td rowspan=1 colspan=1>13.95</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>3.7</td></tr></table>

Lot 2   

<table><tr><td rowspan=1 colspan=3>System: RX daytona plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum Level 1</td><td rowspan=1 colspan=1>3.85</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum Level 2</td><td rowspan=1 colspan=1>6.65</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>SerumLevel 3</td><td rowspan=1 colspan=1>10.70</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Serum ILevel 4</td><td rowspan=1 colspan=1>13.83</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>4.0</td></tr></table>

# Calcium Urine Precision Summary

Lot 1   
Page 4 of 7   

<table><tr><td rowspan=1 colspan=3>System: RX daytona plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 1</td><td rowspan=1 colspan=1>6.05</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 2</td><td rowspan=1 colspan=1>7.94</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 3</td><td rowspan=1 colspan=1>15.07</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 4</td><td rowspan=1 colspan=1>25.97</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>3.9</td></tr></table>

# Confidential

# RANDOX 510(k) Summary: RANDOX CALCIUM (Ca)

Lot 2   

<table><tr><td rowspan=1 colspan=3>System: RX daytona plus</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>Product</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>Urine Level 1</td><td rowspan=1 colspan=1>6.05</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 2</td><td rowspan=1 colspan=1>7.90</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 3</td><td rowspan=1 colspan=1>15.11</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>Ca</td><td rowspan=1 colspan=1>UrineLevel 4</td><td rowspan=1 colspan=1>26.05</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>3.7</td></tr></table>

# b. Linearity/assay reportable range:

Linearity studies have been carried out in accordance with C.L.S.I. standard EP6-A. Linearity studies were performed at 11 levels to determine the analytical range of an assay - that is the range where the reported result is a linear function to the analyte concentration (or where deviation from linearity is less than $5 \%$ ).

The linearity samples were prepared at 11 levels including levels below and above the claimed measuring range.

The results are summarized as follows:

Serum Linearity Summary for Calcium

<table><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>Linear Regression</td><td rowspan=1 colspan=1>Correlation Coefficient r</td><td rowspan=1 colspan=1>Reportable Range</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>y = 1.01x-0.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.0 - 16 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>y = 1.02x + 0.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.0 - 16 mg/dL</td></tr></table>

The reportable range of the assay for serum and plasma samples is $1 . 0 - 1 6 ~ \mathrm { m g / d L }$ .

Urine Linearity Summary for Calcium   

<table><tr><td rowspan=1 colspan=1>Lot</td><td rowspan=1 colspan=1>Linear Regression</td><td rowspan=1 colspan=1>Correlation Coefficient r</td><td rowspan=1 colspan=1>Reportable Range</td></tr><tr><td rowspan=1 colspan=1>Lot 1</td><td rowspan=1 colspan=1>y = 0.99x + 0.20</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.0 - 32 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lot 2</td><td rowspan=1 colspan=1>y = 0.98x + 0.28</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.0 - 32 mg/dL</td></tr></table>

The reportable range of the assay for urine samples is $1 . 0 - 3 2 \ : \mathrm { m g / d L } .$

# c. Analytical Specificity:

The effects of potential interferents were determined by calculating the mean value of the spiked interferent with the corresponding control solution. The spiked sample results were compared to control samples prepared without the potential interferents. Sponsor’s Acceptance Criteria: a deviation of $\leq \pm 1 0 \%$ for the test sample as compared to the control sample.

# Confidential

# Serum Summary

The following analytes were tested up to the levels indicated at Calcium concentrations of 8 mg/dL and $1 2 { \mathrm { m g / d L } }$ and found not to interfere.

# Interferents in serum samples

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=2>Calcium Concentration</td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>8 mg/dL</td><td rowspan=1 colspan=1>12 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Haemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>60 mg/dL</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>60 mg/dL</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>2000 mg/dL</td><td rowspan=1 colspan=1>2000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1315 mg/dL</td><td rowspan=1 colspan=1>2000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

# Urine Summary

The following analytes were tested up to the levels indicated at Calcium concentrations of 9 mg/dL and $2 2 . 8 \ : \mathrm { m g / d L }$ and found not to interfere.

# Interferents in urine samples

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=2>Calcium Concentration</td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>9 mg/dL</td><td rowspan=1 colspan=1>22.8 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Haemoglobin</td><td rowspan=1 colspan=1>250 mg/dl</td><td rowspan=1 colspan=1>250 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Total Bilirubin</td><td rowspan=1 colspan=1>60 mg/dl</td><td rowspan=1 colspan=1>60 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>60 mg/dl</td><td rowspan=1 colspan=1>60 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>200 mg/dl</td><td rowspan=1 colspan=1>200 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000 mg/dl</td><td rowspan=1 colspan=1>1000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Boric Acid</td><td rowspan=1 colspan=1>1000 mg/dl</td><td rowspan=1 colspan=1>1000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Gamma Globulin</td><td rowspan=1 colspan=1>500 mg/dl</td><td rowspan=1 colspan=1>2000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>2000 mg/dl</td><td rowspan=1 colspan=1>2000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>500 mg/dl</td><td rowspan=1 colspan=1>500 mg/dl</td></tr><tr><td rowspan=1 colspan=1>SodiumOxalate</td><td rowspan=1 colspan=1>100 mg/dl</td><td rowspan=1 colspan=1>100 mg/dl</td></tr><tr><td rowspan=1 colspan=1>SodiumFluoride</td><td rowspan=1 colspan=1>1000 mg/dl</td><td rowspan=1 colspan=1>1000 mg/dl</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>4000 mg/dl</td><td rowspan=1 colspan=1>4000 mg/dl</td></tr></table>

# d. Method comparison with predicate device:

Correlation studies were carried out in accordance with C.L.S.I. guideline EP09-A2 ‘Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition.’

# Serum Correlation

111 serum patient samples spanning the range 1.00 to 15.87 mg/dL (0.25 to 3.96 mmol/l) were tested on the RX daytona plus analyzer with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:

# Confidential

# RANDOX 510(k) Summary: RANDOX CALCIUM (Ca)

$y = 0 . 9 9 x - 0 . 1 0$

Correlation coefficient of $\mathsf { r } = 0 . 9 9$

# Urine Correlation

100 urine patient samples spanning the range 1.20 to $3 1 . 7 8 ~ \mathrm { m g / d L }$ (0.3 to 7.93 mmol/l), were tested on the RX daytona plus analyzer with each sample tested in singlicate. The test method was compared to the predicate device and the following linear regression equation was obtained:

$$
y = 0 . 9 8 \times - 0 . 2 4
$$

Correlation coefficient of $\mathsf { r } = 0 . 9 9$ e. Matrix comparison (Serum vs Plasma)

Matrix method comparison for the Calcium assay was tested on one RX daytona Plus system and was assessed for two lots of Calcium reagents. Both serum (x) and lithium heparin plasma (y) were tested to determine whether method accuracy with lithium heparin specimens is equivalent to serum results and that lithium heparin plasma does not interfere with either the method or the system.

Patient samples were drawn in matched pairs – one sample serum $( \mathsf { x } )$ and the second sample lithium heparin plasma (y). 47 matched patient sample pairs were analyzed in singlicate spanning the range 1.00 to $1 4 . 1 1 ~ \mathrm { m g / d L }$ and the following linear regression equation was obtained:

$$
y = 0 . 9 7 x + 0 . 2 2
$$

Correlation coefficient of $\mathsf { r } = 0 . 9 9$

# 10. CONCLUSION

Testing results indicate that the proposed device (RANDOX CALCIUM (Ca)) is safe and effective for the stated intended use and is substantially equivalent to the predicate device.

# Confidential